EE9400366A - Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid - Google Patents

Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid

Info

Publication number
EE9400366A
EE9400366A EE9400366A EE9400366A EE9400366A EE 9400366 A EE9400366 A EE 9400366A EE 9400366 A EE9400366 A EE 9400366A EE 9400366 A EE9400366 A EE 9400366A EE 9400366 A EE9400366 A EE 9400366A
Authority
EE
Estonia
Prior art keywords
interferons
alpha
crystalline
preparation
metal
Prior art date
Application number
EE9400366A
Other languages
English (en)
Inventor
L. Nagabhushhan Tattanahalli
Reichert Paul
Mcnemar Charles
Nagabhushan Nagamani
Tindall Stephen
Hruza Alan
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE9400366A publication Critical patent/EE9400366A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B28/00—Production of homogeneous polycrystalline material with defined structure
    • C30B28/04—Production of homogeneous polycrystalline material with defined structure from liquids
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
EE9400366A 1993-02-25 1994-11-21 Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid EE9400366A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/024,330 US5441734A (en) 1993-02-25 1993-02-25 Metal-interferon-alpha crystals

Publications (1)

Publication Number Publication Date
EE9400366A true EE9400366A (et) 1996-04-15

Family

ID=21820042

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400366A EE9400366A (et) 1993-02-25 1994-11-21 Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid

Country Status (12)

Country Link
US (2) US5441734A (et)
EP (1) EP0686163A1 (et)
JP (1) JPH08503000A (et)
KR (1) KR960701097A (et)
CN (1) CN1120846A (et)
AU (1) AU6299094A (et)
CA (1) CA2156921A1 (et)
EE (1) EE9400366A (et)
FI (1) FI953910A7 (et)
HU (1) HUT72973A (et)
NZ (1) NZ262997A (et)
WO (1) WO1994019373A1 (et)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203319A (es) * 1990-06-04 1992-07-31 Schering Corp Metodo para la preparacion de cristales de alfa-2 interferona.
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5441734A (en) * 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ513163A (en) 1999-03-05 2004-02-27 Genencor Int Method for rapidly obtaining crystals with desirable morphologies
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
KR101431172B1 (ko) * 2003-08-28 2014-08-19 수퍼랩 파 이스트 리미티드 변경된 공간 구조를 갖는 인터페론의 용도
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
WO2006134497A2 (en) * 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
US9157007B2 (en) 2011-03-09 2015-10-13 3D Systems, Incorporated Build material and applications thereof
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
CN107556376B (zh) * 2017-09-08 2018-09-28 上海华新生物高技术有限公司 一种干扰素α-2b突变体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US288203A (en) * 1883-11-13 Stereotyping outfit
US2882034A (en) * 1948-11-01 1959-04-14 North American Aviation Inc Accelerometer and integrator
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
NZ202698A (en) * 1981-12-07 1986-02-21 Hoffmann La Roche Human leukocyte interferon in crystalline form
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
MX9203319A (es) * 1990-06-04 1992-07-31 Schering Corp Metodo para la preparacion de cristales de alfa-2 interferona.
US5441734A (en) * 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals

Also Published As

Publication number Publication date
KR960701097A (ko) 1996-02-24
FI953910A0 (fi) 1995-08-21
FI953910L (fi) 1995-08-21
WO1994019373A1 (en) 1994-09-01
CA2156921A1 (en) 1994-09-01
EP0686163A1 (en) 1995-12-13
CN1120846A (zh) 1996-04-17
US5441734A (en) 1995-08-15
JPH08503000A (ja) 1996-04-02
HU9502485D0 (en) 1995-10-30
US5602232A (en) 1997-02-11
FI953910A7 (fi) 1995-08-21
AU6299094A (en) 1994-09-14
NZ262997A (en) 1997-07-27
HUT72973A (en) 1996-06-28

Similar Documents

Publication Publication Date Title
EE9400366A (et) Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid
FI960751A7 (fi) Substituoidut atsaindolylideeniyhdisteet ja menetelmä niiden valmistamiseksi
FI954246L (fi) Uusia A83543-yhdisteitä ja menetelmä niiden valmistamiseksi
FI956270L (fi) Piperdiinijohdannaisia ja menetelmä niiden valmistamiseksi
EP0448300A3 (en) Method and composition for coiontophoresis
FI945362L (fi) Menetelmä monosyklopentadienyyli-metallikompleksiyhdisteiden valmistamiseksi ja käyttömenetelmä
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
FI951596L (fi) Menetelmä 10-desasetyylibakkatiini-III:n saamiseksi
FI951184L (fi) Taikinaa sisältävä yhdistelmä sekä menetelmä sen valmistamiseksi
CY2178B1 (en) Naphthyl compounds intermediates compositions and methods
FI930326L (fi) Pinnoiteseos ja menetelmä sen valmistamiseksi
FI930076A7 (fi) Systeamiinia sisältävä permanenttauskoostumus ja menetelmä
FI944136L (fi) Koostumuksia ja menetelmä sialyylitransferaasien identifioimiseksi ja syntesoimiseksi
FI953919A7 (fi) Pyrrolydeenimetyylijohdannaiset ja menetelmä niiden valmistamiseksi
FI943383L (fi) Yhdiste FO-1289 ja menetelmä sen valmistamiseksi
FI943532L (fi) Revinnäismassa ja menetelmä revinnäismassan valmistamiseksi
PL318193A1 (en) Novel streptogramines and method of obtaining them by mutasynthesis
FI955708L (fi) Menetelmä 2-fenyyli-3-aminopiperidiinin valmistamiseksi ja erottamiseksi
FI931612L (fi) Koostumus ja menetelmä korroosion estämiseksi
FI943293L (fi) Raide-elementit ja menetelmä niiden valmistamiseksi
FI955123A0 (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi
FI933642A7 (fi) Koostumus ja menetelmiä luun muodostamiseksi
FI942046L (fi) Polysykliset yhdisteet ja menetelmä niiden valmistamiseksi
FI944842A7 (fi) Fluoratut 4-aminoandrostadienonijohdannaiset ja menetelmä niiden valmi stamiseksi
FI972464L (fi) Diaminoeetterin diklavulanaattisuola ja menetelmä sen valmistamiseksi